Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI + Panitumumab in Elderly Patients With Metastatic Colorectal Cancer
NCT03142516Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by GEMCAD. Primary endpoint: Progression-free survival at one year at 12 months. Started Oct 2017; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03142516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142516.